Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01203514 · ClinicalTrials.gov registry record · Phase 2

The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants

A Phase 2 study, sponsored by NICHD Neonatal Research Network.

Completed
Registry status
Phase 2
Development phase
318
Enrollment target

NCT01203514 is a Phase 2 study that has completed, run by NICHD Neonatal Research Network. The registered enrollment target is 318 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01203514, a Phase 2 study, has completed, sponsored by NICHD Neonatal Research Network.

COMPLETED
Registry status
Phase 2
Development phase
318 participants
Enrollment target

Study Summary

This study tested the safety and efficacy of transfusing erythropoietin (Epo) and iron in infants of \<1,250g birth weight. For infants 401-1,000g birth weight, we tested whether early erythropoietin (Epo) and iron therapy would decrease the number of transfusions received. For infants 1,001-1,250g birth weight, we tested whether early erythropoietin (Epo) and iron therapy would decrease the percentage of infants who received any transfusions.

Interventions

  • OTHER Sham Comparator
  • DRUG Erythropoietin

Trial Details

FieldValue
Enrollment Target 318 participants
Start Date 1997-08
Est. Completion 2000-08
Phase Phase 2

Sponsor

NICHD Neonatal Research Network

61 total trials

What the Registry Record Tells You About NCT01203514

The ClinicalTrials.gov registry entry for NCT01203514 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 318 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NICHD Neonatal Research Network, which has 61 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Sham Comparator is the first listed.

NCT01203514 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01203514 about?

NCT01203514 is a clinical study titled "The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants". This study tested the safety and efficacy of transfusing erythropoietin (Epo) and iron in infants of \<1,250g birth weight. For infants 401-1,000g birth weight, we tested whether early erythropoietin (Epo) and iron therapy would decrease the number of transfusions received. For infants 1,001-1,250g ...

What is the current status of trial NCT01203514?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 318 participants. The study started on 1997-08. Estimated completion is 2000-08.

What interventions are being tested in trial NCT01203514?

The interventions under investigation include: Sham Comparator (OTHER), Erythropoietin (DRUG).

Who is sponsoring clinical trial NCT01203514?

This trial is sponsored by NICHD Neonatal Research Network, which has 61 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.